Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terazosin
Drug ID BADD_D02158
Description Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Indications and Usage Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
Marketing Status approved
ATC Code G04CA03
DrugBank ID DB01162
KEGG ID D08569
MeSH ID C041226
PubChem ID 5401
TTD Drug ID D0P9RF
NDC Product Code 51655-915; 68788-8171; 70518-3211; 70518-3193; 23155-738; 67296-1264; 23155-736; 62135-460; 70518-3272; 62135-459; 23155-735; 23155-737; 71335-9607; 60760-816; 62135-458; 62135-461
UNII 8L5014XET7
Synonyms Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin
Chemical Information
Molecular Formula C19H25N5O4
CAS Registry Number 63590-64-7
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000379%
Abnormal dreams17.15.02.001; 19.02.03.001---
Amblyopia06.02.01.001---
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Arrhythmia02.03.02.001---
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003---
Asthenia08.01.01.0010.000167%-
Asthma10.01.03.010; 22.03.01.002---
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002---
Back pain15.03.04.005--
Body temperature increased13.15.01.001---
Bradycardia02.03.02.0020.000167%-
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Burning sensation08.01.09.029; 17.02.06.001---
Cardiac failure02.05.01.001--
Cerebrovascular accident17.08.01.007; 24.03.05.0010.000112%
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.000245%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages